Stephen Miller
Dermatology · San Antonio, TXNPI 1760454060
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.8%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by AbbVie at 54.6% of the total.
Across 610 payments — averaging $41.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$14K
- Sun Pharmaceutical Industries Inc.$1K
- Ortho Dermatologics, A Division Of Bausch Health US, LLC$1K
- Novartis$1K
- Almirall LLC$1K
- Lilly USA, LLC$665
- plus $6K from 31 others
Across 78 payments — averaging $6973.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$176K
- Novartis$126K
- Eli Lilly$120K
- AbbVie$69K
- Pfizer$35K
- Galderma Research & Development, LLC$15K
- plus $4K from 1 others
What the payments were for
- Consulting fees$8003%
- Speaking & faculty fees$10,83243%
- Food & beverage$13,11152%
- Education$5732%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 191 | $13,820 |
| Sun Pharmaceutical Industries Inc. | 39 | $1,394 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 28 | $1,329 |
| Novartis | 48 | $1,239 |
| Almirall LLC | 18 | $1,026 |
| Lilly USA, LLC | 32 | $665 |
| Galderma Laboratories, L.p. | 30 | $655 |
| Johnson & Johnson | 9 | $610 |
| E.r. Squibb & Sons, L.L.C. | 22 | $578 |
| Incyte Corporation | 25 | $557 |
| Amgen | 20 | $466 |
| Sanofi | 20 | $400 |
| VYNE Pharmaceuticals Inc. | 9 | $338 |
| Pfizer | 25 | $283 |
| LEO Pharma Inc. | 12 | $258 |
| UCB, Inc. | 12 | $227 |
| Mayne Pharma Commercial LLC | 14 | $219 |
| Journey Medical Corporation | 6 | $196 |
| Arcutis Biotherapeutics, Inc. | 8 | $147 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $136 |
| Boehringer Ingelheim | 6 | $116 |
| Biofrontera Inc. | 7 | $102 |
| Revance Therapeutics, Inc. | 3 | $90 |
| Stryker | 3 | $79 |
| EPI Health, LLC | 4 | $70 |
| Regeneron Healthcare Solutions, Inc. | 4 | $65 |
| Dermavant Sciences, Inc. | 3 | $58 |
| Fresenius Kabi USA, LLC | 1 | $25 |
| Strata Skin Sciences, Inc. | 2 | $25 |
| Janssen Scientific Affairs, LLC | 1 | $25 |
| Bayer | 1 | $24 |
| Regeneron | 1 | $21 |
| Aclaris Therapeutics, Inc. | 1 | $16 |
| Mylan Pharmaceuticals Inc. | 1 | $15 |
| Encore Dermatology Inc. | 1 | $15 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
| Sebela Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,316 in reported general payments places this provider in the 85th percentile of 1,098 dermatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 16 | $114,085 |
| Taltz AutoinjectorIxekizumab | 11 | $71,203 |
| Azelaic Acid | 24 | $3,949 |
| Clobetasol Propionate | 55 | $2,772 |
| Fluorouracil | 32 | $2,119 |
| Doxycycline Monohydrate | 48 | $1,887 |
| Desonide | 24 | $1,738 |
| Ciclopirox | 37 | $1,689 |
| Ketoconazole | 83 | $1,561 |
| Fluocinonide | 42 | $1,519 |
| Metronidazole | 12 | $688 |
| Clindamycin Phosphate | 15 | $390 |
| Triamcinolone Acetonide | 61 | $300 |
| Mupirocin | 27 | $195 |
| Hydroxyzine Hcl | 30 | $189 |
Paid to pharmacies, not to this prescriber.
Other dermatology in San Antonio
- William CragunSan Antonio$2.2M
- Emily BeckerSan Antonio$1.2M
- Lindsey FinkleaSan Antonio$435K
- John BrowningSan Antonio$351K
- Vivian BucaySan Antonio$241K
- Annabelle GarciaSan Antonio$215K
- Edward LainAustin$2.5M
- Alpesh DesaiHouston$1.6M
- Craig TellerBellaire$1.3M
- Jennifer CatherDallas$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.